Independent Franchise Partners Llp Has Cut Johnson & Johnson (JNJ) Holding By $6.26 Million; Glycomimetics (GLYC)’s Sentiment Is 2.5

May 27, 2018 - By Ann Lacey

Johnson & Johnson (NYSE:JNJ) Logo

Glycomimetics Inc (GLYC) investors sentiment increased to 2.5 in 2017 Q4. It’s up 1.42, from 1.08 in 2017Q3. The ratio has improved, as 50 hedge funds started new or increased holdings, while 20 cut down and sold holdings in Glycomimetics Inc. The hedge funds in our database reported: 30.92 million shares, up from 28.80 million shares in 2017Q3. Also, the number of hedge funds holding Glycomimetics Inc in top ten holdings was flat from 2 to 2 for the same number . Sold All: 6 Reduced: 14 Increased: 22 New Position: 28.

Independent Franchise Partners Llp decreased Johnson & Johnson (JNJ) stake by 0.7% reported in 2017Q4 SEC filing. Independent Franchise Partners Llp sold 45,063 shares as Johnson & Johnson (JNJ)’s stock declined 9.21%. The Independent Franchise Partners Llp holds 6.38M shares with $891.85 million value, down from 6.43M last quarter. Johnson & Johnson now has $325.80 billion valuation. The stock increased 0.10% or $0.12 during the last trading session, reaching $121.47. About 4.59M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 1.12% since May 27, 2017 and is uptrending. It has underperformed by 10.43% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 6 selling transactions for $879,470 activity.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $754.65 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

Nea Management Company Llc holds 5.97% of its portfolio in GlycoMimetics, Inc. for 8.58 million shares. Redmile Group Llc owns 1.93 million shares or 1.41% of their US portfolio. Moreover, Bvf Inc Il has 1.01% invested in the company for 497,474 shares. The California-based Eam Investors Llc has invested 0.81% in the stock. Sphera Funds Management Ltd., a Israel-based fund reported 325,000 shares.

More news for GlycoMimetics, Inc. (NASDAQ:GLYC) were recently published by: Seekingalpha.com, which released: “GlycoMimetics’ (GLYC) CEO Rachel King on Q1 2018 Results – Earnings Call Transcript” on May 06, 2018. Globenewswire.com‘s article titled: “New Research Coverage Highlights Apollo Commercial Real Estate Finance, Drive Shack, GlycoMimetics, Dycom …” and published on May 22, 2018 is yet another important article.

The stock decreased 1.11% or $0.2 during the last trading session, reaching $17.76. About 207,299 shares traded. GlycoMimetics, Inc. (GLYC) has risen 189.22% since May 27, 2017 and is uptrending. It has outperformed by 177.67% the S&P500.

Analysts await GlycoMimetics, Inc. (NASDAQ:GLYC) to report earnings on August, 2. They expect $-0.33 earnings per share, down 10.00% or $0.03 from last year’s $-0.3 per share. After $-0.33 actual earnings per share reported by GlycoMimetics, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment increased to 0.87 in Q4 2017. Its up 0.04, from 0.83 in 2017Q3. It increased, as 35 investors sold JNJ shares while 884 reduced holdings. 143 funds opened positions while 654 raised stakes. 1.72 billion shares or 0.40% more from 1.71 billion shares in 2017Q3 were reported. Moreover, Pictet & Cie (Europe) Sa has 1.32% invested in Johnson & Johnson (NYSE:JNJ). 80,000 are held by Trb L P. Moreover, Drw Securities Limited Liability has 0.55% invested in Johnson & Johnson (NYSE:JNJ). Twin Focus Ltd Liability Company holds 0.21% or 2,960 shares. New York-based Morgan Stanley has invested 0.82% in Johnson & Johnson (NYSE:JNJ). Bbr Prtn Limited Company accumulated 2,900 shares. Tradition Cap Ltd Liability holds 40,791 shares or 1.55% of its portfolio. Lsv Asset Mgmt holds 2.03% in Johnson & Johnson (NYSE:JNJ) or 9.19M shares. Smith And Howard Wealth Mgmt Limited Liability Company accumulated 2,225 shares or 0.15% of the stock. Birch Hill Invest Advsrs Lc reported 212,205 shares stake. Private Ocean Limited Liability Corp has invested 0.01% in Johnson & Johnson (NYSE:JNJ). Boulegeris Invs owns 125,211 shares for 9.1% of their portfolio. Optimum Inv Advsrs accumulated 14,337 shares. Peoples Services Corporation holds 26,678 shares or 2.04% of its portfolio. Messner & Smith Theme Value Investment Ca has 0.6% invested in Johnson & Johnson (NYSE:JNJ).

Since February 15, 2018, it had 0 insider purchases, and 1 sale for $20.17 million activity. Stoffels Paulus had sold 155,342 shares worth $20.17M.

Independent Franchise Partners Llp increased Philip Morris Intl Inc (NYSE:PM) stake by 1.13 million shares to 4.92M valued at $519.84 million in 2017Q4. It also upped Oracle Corp (NYSE:ORCL) stake by 291,286 shares and now owns 17.65 million shares. Kimberly Clark Corp (NYSE:KMB) was raised too.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 11 have Buy rating, 5 Sell and 7 Hold. Therefore 48% are positive. Johnson & Johnson had 101 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, January 25. The stock of Johnson & Johnson (NYSE:JNJ) has “Hold” rating given on Friday, June 16 by Jefferies. The rating was upgraded by Barclays Capital on Tuesday, December 1 to “Overweight”. Atlantic Securities downgraded Johnson & Johnson (NYSE:JNJ) rating on Friday, July 21. Atlantic Securities has “Sell” rating and $11300 target. As per Tuesday, January 23, the company rating was maintained by BTIG Research. The company was maintained on Tuesday, August 25 by Cowen & Co. The company was maintained on Tuesday, July 18 by Stifel Nicolaus. Piper Jaffray maintained it with “Hold” rating and $120.0 target in Monday, October 2 report. The stock of Johnson & Johnson (NYSE:JNJ) has “Buy” rating given on Friday, January 12 by Wells Fargo. Goldman Sachs maintained Johnson & Johnson (NYSE:JNJ) on Wednesday, April 20 with “Neutral” rating.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: